T1 Level 788 792 cell
T2 Protein 490 498 REV-ERBβ
T3 Protein 960 963 p53
T4 Condition 1614 1644 malignant and benign neoplasms
T5 Gene 1194 1230 REV-ERB agonists impair glioblastoma
T7 Level 723 740 melanocytic naevi
T9 Protein 1520 1528 agonists
T10 Condition 810 820 anticancer
T11 Protein 596 604 agonists
T12 Protein 1060 1066 SR9011
T13 Protein 429 463 nuclear hormone receptors REV-ERBα
T14 Gene 1194 1210 REV-ERB agonists
T15 Level 781 793 normal cells
T16 Level 669 673 cell
T17 Protein 479 484 NR1D1
T18 Intervention 797 804 tissues
T19 Protein 628 638 SR9011—are
T20 Protein 608 616 REV-ERBs
T21 Protein 94 97 DNA
T22 Level 45 49 cell
T23 Protein 617 623 SR9009
T24 Protein 1049 1055 SR9009
T25 Protein 910 916 PIK3CA
T26 Intervention 1402 1412 antitumour
T27 Level 662 711 cancer cells and oncogene-induced senescent cells
T28 Condition 243 249 tumour
T29 Protein 628 634 SR9011
T30 Protein 904 908 BRAF
T31 Protein 844 850 SR9011
T32 Species 1301 1305 mice
T33 Protein 514 519 NR1D2
T34 Level 706 710 cell
T35 Condition 1163 1173 anticancer
T36 Protein 415 423 REV-ERBs
T37 Condition 407 413 cancer
T38 Protein 564 572 clock5,6
T39 Protein 833 839 SR9009
T42 Disease 1289 1297 toxicity
T45 Level 1123 1138 malignant cells
T46 Gene 1512 1528 REV-ERB agonists
T47 Condition 662 668 cancer
T48 Condition 1446 1456 anticancer
T49 Level 1133 1137 cell
